Literature DB >> 1953001

Bone marrow transplantation in sickle cell anaemia.

C Vermylen1, G Cornu, M Philippe, J Ninane, A Borja, D Latinne, A Ferrant, J L Michaux, G Sokal.   

Abstract

Sickle cell anaemia is still responsible for severe crippling and death in young patients living in developing countries. Apart from prophylaxis and treatment of infections, no active treatment can be safely proposed in such areas of the world. Therefore a bone marrow transplantation was performed in 12 patients staying in Belgium and planning to return to Africa. Twelve patients, aged between 11 months and 23 years (median 4 years), underwent a HLA identical bone marrow transplantation. The conditioning regimen included oral busulphan for four consecutive days (4 mg/kg) followed by four days of intravenous cyclophosphamide (50 mg/kg). In 10 patients the engraftment was rapid and sustained. A further patient suffered transient red cell hypoplasia and another underwent a second bone marrow transplantation from the same donor at day 62 because of graft rejection. All patients are alive and well with a follow up ranging from 9-51 months (median 27 months). In all cases a complete cessation of vaso-occlusive episodes and haemolysis was observed as was a change in the haemoglobin pattern in accordance with the donor's electrophoretic pattern.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1953001      PMCID: PMC1793516          DOI: 10.1136/adc.66.10.1195

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  18 in total

1.  Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons.

Authors:  A Al-Khatti; R W Veith; T Papayannopoulou; E F Fritsch; E Goldwasser; G Stamatoyannopoulos
Journal:  N Engl J Med       Date:  1987-08-13       Impact factor: 91.245

2.  The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire.

Authors:  N Nzilambi; K M De Cock; D N Forthal; H Francis; R W Ryder; I Malebe; J Getchell; M Laga; P Piot; J B McCormick
Journal:  N Engl J Med       Date:  1988-02-04       Impact factor: 91.245

3.  Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease.

Authors:  A J Keidan; M C Sowter; C S Johnson; S S Marwah; J Stuart
Journal:  Clin Sci (Lond)       Date:  1989-04       Impact factor: 6.124

4.  Use of piracetam improves sickle cell deformability in vitro and in vivo.

Authors:  E K Gini; J Sonnet
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

Review 5.  Management of sickle cell disease.

Authors:  M Brozović; S Davies
Journal:  Postgrad Med J       Date:  1987-08       Impact factor: 2.401

6.  Bone-marrow transplantation in a patient with sickle-cell anemia.

Authors:  F L Johnson; A T Look; J Gockerman; M R Ruggiero; L Dalla-Pozza; F T Billings
Journal:  N Engl J Med       Date:  1984-09-20       Impact factor: 91.245

7.  Treatment of sickle cell anemia with hydroxyurea and erythropoietin.

Authors:  M A Goldberg; C Brugnara; G J Dover; L Schapira; S Charache; H F Bunn
Journal:  N Engl J Med       Date:  1990-08-09       Impact factor: 91.245

8.  Early deaths in Jamaican children with sickle cell disease.

Authors:  D W Rogers; J M Clarke; L Cupidore; A M Ramlal; B R Sparke; G R Serjeant
Journal:  Br Med J       Date:  1978-06-10

9.  Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin.

Authors:  R Storb; P L Weiden; K M Sullivan; F R Appelbaum; P Beatty; C D Buckner; R A Clift; K C Doney; J Hansen; P J Martin
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

10.  Bone marrow transplantation in five children with sickle cell anaemia.

Authors:  C Vermylen; E Fernandez Robles; J Ninane; G Cornu
Journal:  Lancet       Date:  1988-06-25       Impact factor: 79.321

View more
  3 in total

1.  Using a mock trial to make a difficult clinical decision.

Authors:  R Smith
Journal:  BMJ       Date:  1992-11-21

Review 2.  Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Authors:  Gregory M T Guilcher; Tony H Truong; Santosh L Saraf; Jacinth J Joseph; Damiano Rondelli; Matthew M Hsieh
Journal:  Semin Hematol       Date:  2018-04-25       Impact factor: 3.851

3.  Bone marrow transplants in genetic diseases.

Authors:  J R Hobbs
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.